What is Lyndra Therapeutics?
Founded in 2015 and headquartered in Watertown, Massachusetts, Lyndra Therapeutics operates at the forefront of pharmaceutical manufacturing and drug delivery innovation. The company specializes in creating oral, long-acting therapies designed to improve patient outcomes by simplifying medication regimens. By addressing the critical challenge of medication adherence, Lyndra is carving out a significant market position within the specialty pharmaceutical sector. Their platform technology is engineered to provide sustained drug release, potentially reducing the burden of daily dosing for patients managing chronic conditions. This strategic focus on high-impact therapeutic delivery has attracted substantial interest from both venture capital firms and industry-specific strategic partners, enabling the company to scale its operations and research capabilities effectively.
How much funding has Lyndra Therapeutics raised?
Lyndra Therapeutics has raised a total of $239.5M across 4 funding rounds:
Series A
$23M
Series B
$55M
Series C
$60.5M
Series E
$101M
Series A (2018): $23M with participation from Polaris Partners
Series B (2019): $55M, investors not publicly disclosed
Series C (2021): $60.5M supported by Invus, Polaris Partners, Limitless Ventures, Yipinhong Pharmaceutical Co., and AIG Global Investment Group
Series E (2023): $101M featuring Polaris Partners, Sarissa Capital Acquisition, and Sun Pharma
Key Investors in Lyndra Therapeutics
Polaris Partners
Polaris Partners is a venture capital firm that specializes in backing transformational companies in the biotech and healthcare sectors, providing deep operational expertise and strategic guidance.
Sarissa Capital Acquisition
Sarissa Capital Acquisition Corp. is an investment entity focused on identifying and executing strategic business combinations, mergers, and asset acquisitions within the healthcare and life sciences industries.
Sun Pharma
Sun Pharma is a global specialty generic pharmaceutical leader that manufactures and distributes complex formulations and active pharmaceutical ingredients, bringing significant industry scale to its investment portfolio.
What's next for Lyndra Therapeutics?
With the successful closure of its latest funding round, Lyndra Therapeutics is poised to accelerate its clinical development programs and expand its manufacturing infrastructure. The strategic roadmap likely involves scaling the production of its lead candidates while simultaneously exploring new therapeutic areas where long-acting delivery can provide a competitive advantage. As the company moves closer to potential market entry, the focus will shift toward regulatory engagement and the establishment of commercial partnerships. The continued backing from seasoned investors suggests a long-term commitment to the company's vision of redefining standard-of-care protocols through technological innovation in drug administration.
See full Lyndra Therapeutics company page
